Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s footer software/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check54 days agoChange DetectedSite revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check61 days agoChange DetectedFooter revision updated from Revision: v3.4.2 to Revision: v3.4.3.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision updated to v3.4.2 and the prior funding/operating-status notice was removed; these are site-wide housekeeping changes rather than updates to study details.SummaryDifference0.4%

- Check96 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the system revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.